tailieunhanh - báo cáo khoa học: " Mature autologous dendritic cell vaccines in advanced non-small cell lung cancer: a phase I pilot study"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Mature autologous dendritic cell vaccines in advanced non-small cell lung cancer: a phase I pilot study | Perroud et al. Journal of Experimental Clinical Cancer Research 2011 30 65 http content 30 1 65 Journal of Experimental Clinical Cancer Research RESEARCH Open Access Mature autologous dendritic cell vaccines in advanced non-small cell lung cancer a phase I pilot study Mauricio W Perroud Jr1 Helen N Honma1 Aristóteles S Barbeiro1 Simone CO Gilli2 Maria T Almeida2 José Vassallo3 Sara TO Saad2 and Lair Zambon1 Abstract Background Overall therapeutic outcomes of advanced non-small-cell lung cancer NSCLC are poor. The dendritic cell DC immunotherapy has been developed as a new strategy for the treatment of lung cancer. The purpose of this study was to evaluate the feasibility safety and immunologic responses in use in mature antigen-pulsed autologous DC vaccine in NSCLC patients. Methods Five HLA-A2 patients with inoperable stage III or IV NSCLC were selected to receive two doses of 5 X 107 DC cells administered subcutaneous and intravenously two times at two week intervals. The immunologic response safety and tolerability to the vaccine were evaluated by the lymphoproliferation assay and clinical and laboratorial evolution respectively. Results The dose of the vaccine has shown to be safe and well tolerated. The lymphoproliferation assay showed an improvement in the specific immune response after the immunization with a significant response after the second dose p . This response was not long lasting and a tendency to reduction two weeks after the second dose of the vaccine was observed. Two patients had a survival almost twice greater than the expected average and were the only ones that expressed HER-2 and CEA together. Conclusion Despite the small sample size the results on the immune response safety and tolerability combined with the results of other studies are encouraging to the conduction of a large clinical trial with multiples doses in patients with early lung cancer who underwent surgical treatment. Trial Registration Current Controlled .

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN
crossorigin="anonymous">
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.